Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Daiichi Sankyo Ltd ADR (OP: DSNKY )

29.81 +1.03 (+3.58%)
Streaming Delayed Price Updated: 11:43 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Daiichi Sankyo Ltd ADR

< Previous 1 2 Next >
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free... 
Via Benzinga
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... 
Via Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to... 
Via Benzinga
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024
Daiichi Sankyo Co just reported results for the first quarter of 2024. 
Via InvestorPlace
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
"As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say. 
Via Benzinga
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
Via Benzinga
Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
Via Benzinga
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises... 
Via Benzinga
Exposures Product Safety
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
Undervalued Nasdaq 100 stocks may not be as rare as hen's teeth but not quite so plentiful amid a raging bull market. 
Via InvestorPlace
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The... 
Via Benzinga
Exposures Product Safety
Why Is AstraZeneca Stock Trading Lower On Tuesday?
AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance. 
Via Benzinga
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023
Daiichi Sankyo Co just reported results for the third quarter of 2023. 
Via InvestorPlace
Double Good News For AstraZeneca's Breast Cancer Drugs
Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer. 
Via Benzinga
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal... 
Via Benzinga
Exposures Product Safety
What's Going On With Pfizer Stock Today?
Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues. 
Via Benzinga
Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares are trading lower on Wednesday after the company announced a $125 million amendment to the collaboration with Japanese pharma company Daiichi Sankyo... 
Via Benzinga
Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
Japanese stocks are gaining favor among I-banks and sport attractive valuations; here are 3 stocks with low P/B that have outperformed and could generate shareholder wealth. 
Via Benzinga
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
In due time, its new partnership with Daiichi Sankyo could be massive. 
Via The Motley Fool
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:  
Via Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria 
Via Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in 
Via Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung... 
Via Benzinga
Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
Australia biotech startup Psylo has inked a sponsored research agreement with global Japanese pharmaceutical company Daiichi Sankyo (OTCMKTS: DSNKY) toward advancing antidepressant psychiatric... 
Via Benzinga
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Via Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward. 
Via The Motley Fool
AstraZeneca’s Next “Wonder Drug”
Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential to become a key... 
Via Talk Markets
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
Via Benzinga
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
Via Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.